VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Clinical development of antiangiogenic agents, particularly vascular endothelial growth factor (VEGF) inhibitors, has accelerated significantly.
• Three direct VEGF pathway inhibitors are currently approved for cancer therapy, with others in advanced clinical development showing promising results.

Purpose of the Study:

• To discuss the crucial questions surrounding the use of novel molecular-targeted anti-VEGF agents in cancer therapy.
• To explore potential mechanisms of action for anti-VEGF therapy, including tumor vascular normalization, blockade of bone marrow-derived cell recruitment, and cytostatic effects.
• To review the progress, challenges, and future directions in anti-cancer therapy utilizing anti-VEGF agents, focusing on clarifying molecular mechanisms and validating biomarkers.

Main Methods:

• Review of current clinical development progress for antiangiogenic agents.
• Discussion of potential mechanisms of action for anti-VEGF therapy.
• Analysis of challenges and future directions in the field.

Main Results:

• Significant acceleration in the clinical development of antiangiogenic agents.
• Approval of three direct VEGF pathway inhibitors for cancer therapy.
• Promising results from other VEGF pathway inhibitors in advanced clinical development.

Conclusions:

• Clarification of the underlying molecular mechanisms of action for anti-VEGF therapy is essential.
• Identification and validation of biomarkers are critical for optimizing the use of anti-VEGF agents.
• Further research is needed to address the optimal use of these agents, alone or in combination therapies.